KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer

被引:97
作者
Franklin, Wilbur A. [1 ]
Haney, Jerry [1 ]
Sugita, Michio [1 ]
Bemis, Lynne [2 ]
Jimeno, Antonio [2 ]
Messersmith, Wells A. [2 ]
机构
[1] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA
[2] Univ Colorado Denver, Dept Med Oncol, Aurora, CO 80045 USA
关键词
RESOLUTION MELTING ANALYSIS; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR; K-RAS MUTATIONS; POINT MUTATION; AMPLIFICATION; CHEMOTHERAPY; ERLOTINIB; CETUXIMAB;
D O I
10.2353/jmoldx.2010.080131
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Treatment of colon carcinoma with the anti-epidermal growth factor receptor antibody Cetuximab is reported to be ineffective in KRAS-mutant tumors. Mutation testing techniques have therefore become an urgent concern. We have compared three methods for detecting KRAS mutations in 59 cases of colon carcinoma: 1) high resolution melting, 2) the amplification refractory mutation system using a bifunctional self-probing primer (ARMS/Scorpion, ARMS/S), and 3) direct sequencing. We also evaluated the effects of the methods of sectioning and coring of paraffin blocks to obtain tumor DNA on assay sensitivity and specificity. The most sensitive and specific combination of block sampling and mutational analysis was ARMS/S performed on DNA derived from 1-mm paraffin cores. This combination of tissue sampling and testing method detected KRAS mutations in 46% of colon tumors. Four samples were positive by ARMS/S, but initially negative by direct sequencing. Cloned DNA samples were retested by direct sequencing, and in all four cases KRAS mutations were identified in the DNA. in six cases, high resolution melting abnormalities could not be confirmed as specific mutations either by ARMS/S or direct sequencing. We conclude that coring of the paraffin blocks and testing by ARMS/S is a sensitive, specific, and efficient method for KRAS testing. (J Mol Diagn 2010, 12:43-50; DOI: 10.2353/jmoldx.2010.080131)
引用
收藏
页码:43 / 50
页数:8
相关论文
共 27 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   K-ras mutations in non-small-cell lung carcinoma:: A review [J].
Aviel-Ronen, Sarit ;
Blackhall, Fiona H. ;
Shepherd, Frances A. ;
Tsao, Ming-Sound .
CLINICAL LUNG CANCER, 2006, 8 (01) :30-38
[3]  
Clayton SJ, 2000, CLIN CHEM, V46, P1929
[4]   High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies [J].
Do, Hongdo ;
Krypuy, Michael ;
Mitchell, Paul L. ;
Fox, Stephen B. ;
Dobrovic, Alexander .
BMC CANCER, 2008, 8 (1)
[5]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909
[6]   The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system [J].
Fox, JC ;
England, J ;
White, P ;
Ellison, G ;
Callaghan, K ;
Charlesworth, NR ;
Hehir, J ;
McCarthy, TL ;
Smith-Ravin, J ;
Talbot, IC ;
Snary, D ;
Northover, JMA ;
Newton, CR ;
Little, S .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1267-1274
[7]   Methods of molecular analysis: mutation detection in solid tumours [J].
Frayling, IM .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2002, 55 (02) :73-79
[8]   Amplicon melting analysis with labeled primers: A closed-tube method for differentiating homozygotes and heterozygotes [J].
Gundry, CN ;
Vandersteen, JG ;
Reed, GH ;
Pryor, RJ ;
Chen, J ;
Wittwer, CT .
CLINICAL CHEMISTRY, 2003, 49 (03) :396-406
[9]   High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples:: KRAS codon 12 and 13 mutations in non-small cell lung cancer [J].
Krypuy, Michael ;
Newnham, Genni M. ;
Thomas, David M. ;
Conron, Matthew ;
Dobrovic, Alexander .
BMC CANCER, 2006, 6 (1)
[10]   KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].
Lievre, Astrid ;
Bachet, Jean-Baptiste ;
Boige, Valerie ;
Cayre, Anne ;
Le Corre, Delphine ;
Buc, Emmanuel ;
Ychou, Marc ;
Bouche, Olivier ;
Landi, Bruno ;
Louvet, Christophe ;
Andre, Thierry ;
Bibeau, Frederic ;
Diebold, Marie-Daniele ;
Rougier, Philippe ;
Ducreux, Michel ;
Tomasic, Gorana ;
Emile, Jean-Francois ;
Penault-Llorca, Frederique ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379